Iressa (gefitinib)
- Region
- 🇪🇺 EU
- Active substance
- gefitinib
- Company
- AstraZeneca AB
- Status
- Authorised
- Therapeutic area
- Carcinoma, Non-Small-Cell Lung
- EU approval
- Wed 24 Jun 2009
- Application
- EMEA/H/C/001016
- ATC
- L01XE02
- Official record
- www.ema.europa.eu
Indication
Iressa is indicated for the treatment of adult patients with locally advanced or metastatic non-small-cell lung cancer with activating mutations of epidermal-growth-factor-receptor tyrosine kinase.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Gefitinib Mylan Withdrawn · Mylan Pharmaceuticals Limited
Follow Iressa
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.